Sensyne Health signs agreement with Bayer

Clinical AI technology company, Sensyne Health has signed an initial two-year collaboration agreement with pharmaceutical and life sciences group Bayer.

The agreement aims to accelerate the clinical development of new treatments for cardiovascular disease. 

Under the agreement, Sensyne Health’s proprietary clinical AI technology platform will be used as part of the treatment. 

The initial agreement will generate revenues for Sensyne Health of £5m across the two-year collaboration. Sensyne Health’s partner NHS trusts will receive a 4% share of all revenues generated by the healthcare technology company under this collaboration. This will be in addition to the NHS Trust’s existing shareholdings in Sensyne Health plc.

Paul Drayson, CEO of Sensyne Health plc, said: ‘We are delighted to announce this new agreement with Bayer, which aims to accelerate the clinical development of new treatments for cardiovascular disease, a clinical priority for the NHS, using Sensyne Health’s proprietary clinical AI technology platform.’